 Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in UAMS Profiles by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 | | 2021 | 2 | 0 | 2 | | 2020 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2014 | 1 | 1 | 2 | | 2013 | 1 | 0 | 1 | | 2012 | 1 | 0 | 1 | | 2010 | 2 | 0 | 2 | | 2009 | 0 | 1 | 1 | | 2008 | 1 | 1 | 2 | | 2007 | 2 | 4 | 6 | | 2006 | 1 | 3 | 4 | | 2005 | 3 | 2 | 5 | | 2004 | 1 | 1 | 2 | | 2003 | 1 | 1 | 2 | | 2001 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1997 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles over the past ten years.
-
Halada S, Casado-Medrano V, Baran JA, Lee J, Chinmay P, Bauer AJ, Franco AT. Hormonal Crosstalk Between Thyroid and Breast Cancer. Endocrinology. 2022 07 01; 163(7).
-
Weiser R, Polychronopoulou E, Kuo YF, Haque W, Hatch SS, Tyler DS, Gradishar WJ, Klimberg VS. De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough? Ann Surg. 2021 10 01; 274(4):654-663.
-
Iles KA, Thornton M, Park J, Roberson M, Spanheimer PM, Ollila DW, Gallagher K. Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe? Am Surg. 2022 Mar; 88(3):471-479.
-
Nayyar A, Strassle PD, Iles K, Jameison D, Jadi J, McGuire KP, Gallagher KK. Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women. Ann Surg Oncol. 2020 Nov; 27(12):4853-4860.
-
Heiney SP, Parker PD, Felder TM, Adams SA, Omofuma OO, Hulett JM. A systematic review of interventions to improve adherence to endocrine therapy. Breast Cancer Res Treat. 2019 Feb; 173(3):499-510.
-
Jacob JD, Hodge C, Franko J, Pezzi CM, Goldman CD, Klimberg VS. Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base. J Surg Oncol. 2016 Jun; 113(7):721-5.
-
Zhou DB, Yu L, Du X, Jin J, Cai Z, Chen F, Ke X, Li X, Wu D, Meng F, Ai H, Zhang J, DeMarco D, Chen N, Mei J, Wang J, Hou J. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment. Int J Hematol. 2015 Jun; 101(6):569-77.
-
Leung YK, Chan QK, Ng CF, Ma FM, Tse HM, To KF, Maranchie J, Ho SM, Lau KM. Hsa-miRNA-765 as a key mediator for inhibiting growth, migration and invasion in fulvestrant-treated prostate cancer. PLoS One. 2014; 9(5):e98037.
-
Chau YY, Bandiera R, Serrels A, MartÃnez-Estrada OM, Qing W, Lee M, Slight J, Thornburn A, Berry R, McHaffie S, Stimson RH, Walker BR, Chapuli RM, Schedl A, Hastie N. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol. 2014 Apr; 16(4):367-75.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|